Babak Azad - 09 Nov 2021 Form 4 Insider Report for GoodRx Holdings, Inc. (GDRX)

Role
Chief Marketing Officer and SVP, Marketing & Communications
Signature
/s/ Gracye Cheng, as Attorney-in-Fact for Babak Azad
Issuer symbol
GDRX
Transactions as of
09 Nov 2021
Net transactions value
-$453,591
Form type
4
Filing time
12 Nov 2021, 15:44:00 UTC
Previous filing
13 Oct 2021
Next filing
18 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GDRX Class A Common Stock Options Exercise $74,250 +12,500 $5.94 12,500 09 Nov 2021 Direct
transaction GDRX Class A Common Stock Sale $493,341 -11,700 -94% $42.17* 800 09 Nov 2021 Direct F1, F2
transaction GDRX Class A Common Stock Sale $34,500 -800 -100% $43.12* 0 09 Nov 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GDRX Stock Option (Right to Buy) Options Exercise $0 -12,500 -4.1% $0.000000 292,500 09 Nov 2021 Class A Common Stock 12,500 $5.94 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of December 9, 2020, as amended September 2, 2021.
F2 This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.76 to $42.63. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.82 to $43.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019.

Remarks:

Chief Marketing Officer and SVP, Marketing & Communications